The estimated Net Worth of Ilan Danieli is at least $678 Thousand dollars as of 3 January 2023. Mr Danieli owns over 16,500 units of Precipio Inc stock worth over $342,852 and over the last 7 years he sold PRPO stock worth over $0. In addition, he makes $334,892 as Founder, Pres, and CEO & Director at Precipio Inc.
Mr has made over 14 trades of the Precipio Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 16,500 units of PRPO stock worth $9,900 on 3 January 2023.
The largest trade he's ever made was buying 16,500 units of Precipio Inc stock on 3 January 2023 worth over $9,900. On average, Mr trades about 1,759 units every 50 days since 2017. As of 3 January 2023 he still owns at least 57,046 units of Precipio Inc stock.
You can see the complete history of Mr Danieli stock trades at the bottom of the page.
Ilan Danieli is the Founder, Pres, CEO & Director at Precipio Inc.
As the Founder, Pres, and CEO & Director of Precipio Inc, the total compensation of Mr Danieli at Precipio Inc is $334,892. There are no executives at Precipio Inc getting paid more.
Mr Danieli is 49, he's been the Founder, Pres, and CEO & Director of Precipio Inc since . There are 3 older and 5 younger executives at Precipio Inc. The oldest executive at Precipio Inc is Richard Sandberg, 77, who is the Director.
Ilan's mailing address filed with the SEC is C/O PRECIPIO, INC., 4 SCIENCE PARK, NEW HAVEN, CT, 06511.
Over the last 7 years, insiders at Precipio Inc have traded over $449,545 worth of Precipio Inc stock and bought 88,796 units worth $87,860 . The most active insiders traders include Randal J Kirk, Ronald Asbury Andrews, and Richard A Sandberg. On average, Precipio Inc executives and independent directors trade stock every 54 days with the average trade being worth of $44,781. The most recent stock trade was executed by Richard A Sandberg on 20 January 2023, trading 20,000 units of PRPO stock currently worth $15,600.
precipio is a cancer diagnostics reference laboratory, delivering the latest in advanced diagnostics and personalized medicine. our goal is to assist oncologists in providing the best care for their patients. at the intersection of academia, cancer research, and diagnostics, we connect physicians with world-renown pathologists at the yale school of medicine. at precipio, our customers and their patients benefit from the most accurate, expert diagnosis. we provide our customers exclusive access to some of the most innovative tests in the field of molecular diagnostics, developed through cutting edge research, and the ongoing pursuit and refinement of the science of personalized medicine.
Precipio Inc executives and other stock owners filed with the SEC include: